Related Experiment Video

Updated: Jun 11, 2025

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

1.1K

Addressing the alarming link between nonalcoholic fatty liver disease and cardiovascular mortality in men

Wen-Rui Hao1,2, Chun-Han Cheng3, Tzu-Hurng Cheng4

  • 1Division of Cardiology, Department of Internal Medicine, Shuang Ho Hospital, Ministry of Health and Welfare, Taipei Medical University, New Taipei 23561, Taiwan.

World Journal of Cardiology
|October 1, 2024
PubMed

Insights

Men with non-alcoholic fatty liver disease (NAFLD) face higher cardiovascular mortality risks. Early detection and integrated management are crucial for improving outcomes in these patients.

Area of Science:

  • Cardiology
  • Hepatology
  • Public Health

Background:

  • Nonalcoholic fatty liver disease (NAFLD) is increasingly prevalent globally.
  • Emerging evidence links NAFLD to a heightened risk of cardiovascular disease (CVD).
  • Batta and Hatwal's paper in the World Journal of Cardiology highlights excess cardiovascular mortality in men with NAFLD.

Discussion:

  • This editorial examines the implications of the correlation between NAFLD and increased cardiovascular mortality in men.
  • Potential mechanisms, shared risk factors, and the need for integrated clinical approaches are discussed.
  • The commentary emphasizes early detection, lifestyle modifications, and interdisciplinary collaboration.

Key Insights:

  • NAFLD is a significant, often overlooked, risk factor for cardiovascular mortality in men.
  • A dual burden of NAFLD and cardiovascular disease necessitates a unified management strategy.
  • Proactive management and increased medical community awareness are vital.

Outlook:

  • Further research into the pathophysiological links between NAFLD and CVD is warranted.
  • Developing integrated screening protocols for cardiovascular risk in NAFLD patients is essential.
  • Promoting lifestyle interventions should be a cornerstone of managing both conditions.

Keywords:
Cardiovascular mortalityIntegrated clinical approachesMen's healthNon-alcoholic fatty liver diseaseRisk factors

More Related Videos

A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium08:35

A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium

Published on: May 18, 2021

6.2K
Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

812

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
3
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
2
Coronary Artery Disease IV: Medical Management01:26

Coronary Artery Disease IV: Medical Management

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
11
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
1.1K
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
485
Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
82